RAPP (Rapport Therapeutics) Treasury Stock : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Rapport Therapeutics's treasury stock for the quarter that ended in Dec. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Rapport Therapeutics Treasury Stock Historical Data

The historical data trend for Rapport Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics Treasury Stock Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Treasury Stock

Rapport Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Treasury Stock	Get a 7-Day Free Trial				-	-	-	-	-

Rapport Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.